Ekso Bionics (NASDAQ: EKSO) COO sells 1,320 shares for taxes

Rhea-AI Filing Summary

Ekso Bionics Holdings, Inc. Chief Operating Officer Jason C. Jones reported a sale of company stock in a Form 4 filing. On January 6, 2026, he sold 1,320 shares of common stock at $9.25 per share, with the filing explaining that the sale was made to cover tax withholding obligations from the vesting and settlement of restricted stock awards.

After this transaction, Jones beneficially owned 25,621 shares of Ekso Bionics common stock directly and 3,141 shares indirectly through a 401(k) plan. The filing notes that these share amounts have been adjusted to reflect a 1-for-15 reverse stock split that took effect on June 2, 2025.

Insider Trade Summary

Net Seller: 1,320 shares ($12,210)

Net Sell 2 txns

Insider Jones Jason C

Role Chief Operating Officer

Sold 1,320 shs ($12K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,320	$9.25	$12K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 25,621 shares (Direct); Common Stock — 3,141 shares (Indirect, By 401(k))

Footnotes (1)

1. Represents shares sold by the Reporting Person on January 6, 2026 to cover tax withholding obligations incurred upon the vesting and settlement of restricted stock awards originally reported by the Reporting Person in a Form 4 filed with the Commission on June 15, 2023. These shares were sold in a single transaction at a price of $9.25 per share. On June 2, 2025, the Issuer effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jones Jason C

(Last) (First) (Middle)

101 GLACIER POINT

SUITE A

(Street)

SAN RAFAEL CA 94901

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
EKSO BIONICS HOLDINGS, INC. [ EKSO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/06/2026		S		1,320(1)	D	$9.25(2)	25,621(3)	D
Common Stock								3,141(3)	I	By 401(k)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares sold by the Reporting Person on January 6, 2026 to cover tax withholding obligations incurred upon the vesting and settlement of restricted stock awards originally reported by the Reporting Person in a Form 4 filed with the Commission on June 15, 2023.

2. These shares were sold in a single transaction at a price of $9.25 per share.

3. On June 2, 2025, the Issuer effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

	/s/ Jerome Wong	01/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did EKSO report in this Form 4?

The Form 4 reports that Chief Operating Officer Jason C. Jones sold 1,320 shares of Ekso Bionics common stock on January 6, 2026.

At what price were the EKSO shares sold by the COO?

The 1,320 shares of Ekso Bionics common stock were sold in a single transaction at $9.25 per share.

Why did the EKSO COO sell 1,320 shares?

According to the filing, the shares were sold to cover tax withholding obligations arising from the vesting and settlement of restricted stock awards.

How many EKSO shares does the COO own after this transaction?

Following the reported sale, Jason C. Jones beneficially owned 25,621 shares directly and 3,141 shares indirectly through a 401(k) plan.

Did a reverse stock split affect the share numbers in this EKSO Form 4?

Yes. The filing states that on June 2, 2025, Ekso Bionics effected a 1-for-15 reverse stock split, and the amounts reported in this Form 4 have been adjusted to reflect that split.

What is the role of the reporting person in EKSO?

The reporting person, Jason C. Jones, is the Chief Operating Officer of Ekso Bionics Holdings, Inc.